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Abstract
Background: Better breast cancer prognostication may improve selection of patients for adjuvant
therapy. We conducted a retrospective follow-up study in which we investigated sera of high-risk
primary breast cancer patients, to search for proteins predictive of recurrence free survival.
Methods: Two sample sets of high-risk primary breast cancer patients participating in a
randomised national trial investigating the effectiveness of high-dose chemotherapy were analysed.
Sera in set I (n = 63) were analysed by surface enhanced laser desorption ionisation time-of-flight
mass spectrometry (SELDI-TOF MS) for biomarker finding. Initial results were validated by analysis
of sample set II (n = 371), using one-dimensional gel-electrophoresis.
Results: In sample set I, the expression of a peak at mass-to-charge ratio 9198 (relative intensity
≤ 20 or > 20), identified as haptoglobin (Hp) alpha-1 chain, was strongly associated with recurrence
free survival (global Log-rank test; p = 0.0014). Haptoglobin is present in three distinct phenotypes
(Hp 1-1, Hp 2-1, and Hp 2-2), of which only individuals with phenotype Hp 1-1 or Hp 2-1 express
the haptoglobin alpha-1 chain. As the expression of the haptoglobin alpha-1 chain, determined by
SELDI-TOF MS, corresponds to the phenotype, initial results were validated by haptoglobin
phenotyping of the independent sample set II by native one-dimensional gel-electrophoresis. With
the Hp 1-1 phenotype as the reference category, the univariate hazard ratio for recurrence was
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BMC Cancer 2008, 8:389 http://www.biomedcentral.com/1471-2407/8/3890.87 (95% CI: 0.56 – 1.34, p = 0.5221) and 1.03 (95% CI: 0.65 – 1.64, p = 0.8966) for the Hp 2-1
and Hp 2-2 phenotypes, respectively, in sample set II.
Conclusion: In contrast to our initial results, the haptoglobin phenotype was not identified as a
predictor of recurrence free survival in high-risk primary breast cancer in our validation set. Our
initial observation in the discovery set was probably the result of a type I error (i.e. false positive).
This study illustrates the importance of validation in obtaining the true clinical applicability of a
potential biomarker.
Background
Following lung cancer, breast cancer currently is the sec-
ond leading cause of cancer deaths in women [1]. A sub-
stantial survival benefit is achieved by treatment with
adjuvant systemic therapy. The main prognostic factors in
breast cancer include clinical (age) and pathological
parameters (tumour size, lymph node status, and grade of
malignancy), whereas the hormone-receptor and Her2/
neu-receptor status are (also) predictive factors [2]. How-
ever, 30 – 50% of high-risk primary breast cancer patients
will eventually develop metastatic relapse and die, despite
locoregional treatment and adjuvant systemic chemother-
apy, while there is a small percentage that would have sur-
vived without adjuvant chemotherapy and hormonal
therapy [3]. Clearly, improved breast cancer prognostica-
tion is urgently needed to more accurately predict clinical
outcome in individual patients and as such reduce both
over- and undertreatment of the disease.
High-throughput genomic and transcriptomic
approaches have recently demonstrated to generate signa-
tures that better predict clinical outcome than conven-
tional prognosis criteria. For example, investigators from
our respective institutes have published gene expression
profiles in tumour tissue that outperformed all clinical
variables in predicting disease outcome (risk of recur-
rence) [4-7]. Similarly, a RT-PCR based multigene assay
was recently shown to accurately predict both the proba-
bility of recurrence and the magnitude of chemotherapy
benefit in node-negative, oestrogen-receptor positive
breast cancer [8].
An alternative and complementary approach is to perform
protein expression analysis. As the proteome reflects gene
expression as well as protein stability and post-transla-
tional modifications, protein data could, in principle, be
used for the same purpose. One of the techniques cur-
rently applied in proteomics research of breast cancer is
surface-enhanced laser desorption ionisation time of
flight mass spectrometry (SELDI-TOF MS). Until now,
only two studies have been published in which this plat-
form was applied in the identification of serum markers
for prognosis of breast cancer [9,10]. Comparing the
tumour cytosolic extract of node-negative sporadic breast
tumours with or without a recurrence, Ricolleau et al. [10]
identified a high level of ubiquitin and/or a low level of
ferritin light chain to be associated with a good prognosis
in breast cancer (n = 60). Goncalves et al. [9] constructed
a multiprotein model, consisting of 40 proteins, that cor-
rectly predicted relapse in 67 of the 81 patients of which
fractionated sera were investigated. These promising
results need to be interpreted cautiously, as in both stud-
ies only a limited number of patients was investigated,
and results have not been validated yet by analysis of
independent study populations.
Hence, the aim of the current study is to investigate sera of
high-risk primary breast cancer patients to search for pro-
teins predictive of recurrence free survival, and to validate
our results by analysis of an independent study popula-
tion.
Methods
Study population
From 1993 to 1999, high-risk primary breast cancer
patients who had undergone modified radical mastec-
tomy or breast conserving surgery with complete axillary
clearance participated in a randomised multicentre phase
III trial. This study investigated the benefit of high-dose
adjuvant chemotherapy in patients with ≥ 4 axillary
lymph node metastases. The design of the study has been
described elsewhere [11]. Major eligibility criteria were
histologically confirmed stage IIA, IIB or IIIA breast cancer
with at least 4 tumour-positive axillary lymph nodes but
no evidence of distant metastases, age under 56 years, and
no previous other malignancies.
In sample set I, sera of 63 study patients who were treated
in the Netherlands Cancer Institute were included. Sera
were procured after surgery (7 – 51 days), but prior to
adjuvant chemotherapy (0 – 45 days). All sera were
obtained and stored under strictly defined conditions at
the Institutional Serum Bank. In sample set II, serum/
plasma samples (procured at any time point in therapy) of
371 study patients treated in the Netherlands Cancer Insti-
tute (sera; n = 15, plasma; n = 38), the Erasmus Medical
Center – Daniel den Hoed Cancer Center (sera; n = 114),
the Radboud University Medical Center Nijmegen (sera; n
= 87), the University Medical Center Groningen (sera; n =
69), and the University Medical Center Leiden (sera; n =Page 2 of 15
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cal-ethics approval and all patients gave informed con-
sent.
Chemicals
All used chemicals were obtained from Sigma, St. Louis,
MO, USA, unless stated otherwise.
Biomarker discovery
Protein profiling was performed using the ProteinChip
SELDI Reader (Bio-Rad Laboratories, Hercules, CA, USA).
Several chromatographic array surfaces with suitable
binding conditions were screened for discriminative
mass-to-charge ratio's (m/z) between unfractionated sera
of breast cancer patients of set I either experiencing a
recurrence at a relatively short follow-up (Recurrence Free
Survival (RFS) < 16 months, n = 4), or experiencing no
recurrence after a long follow-up (> 75 months, n = 4).
Optimal discrimination between both groups was
obtained by Q10 arrays (strong anion exchange chroma-
tography) with 100 mM Tris-HCl pH 8/0.1% TritonX-100
as a binding buffer. This assay was subsequently applied
in the analysis of all sera in sample set I (n = 63).
In brief, samples were thawed on ice and denatured by
1:10 dilution in 9 M urea/2% 3- [(3-cholamidopro-
pyl)dimethylammonio]-1-propanesulfonate (CHAPS)/
1% dithiotreitol (DTT). Arrays were assembled in a 96-
well bioprocessor (Bio-Rad Labs), which was placed on a
platform shaker at 350 rpm at all steps of the protocol.
Arrays were equilibrated twice with 200 μl of binding
buffer for 5 min. Pretreated serum samples were diluted
1:10 in binding buffer and were randomly applied to the
arrays. After a 30 min incubation, the arrays were washed
twice with binding buffer and twice with 100 mM Tris-
HCl pH 8 for 5 min. Following a quick rinse with deion-
ised water (Braun, Emmenbrücke, Germany), arrays were
air-dried. A 50% solution of sinapinic acid (Bio-Rad Labs)
in 50% acetonitrile (ACN)/0.5% trifluoroacetic acid
(TFA) was applied twice (1.0 μl) to the array as matrix.
Following air-drying, the arrays were analysed using the
ProteinChip SELDI (PBS IIc) Reader (Bio-Rad Labs). For
mass accuracy, the instrument was calibrated on the day
of measurements with All-In-One peptide standard (Bio-
Rad Labs). Data were collected between 0 and 200 kDa,
averaging 65 laser shots with intensity 158, detector sensi-
tivity 5, and a focus lag time of 746 ns. Spectra were base-
line subtracted and normalised to the total ion current
from 1.5 to 200 kDa. The Biomarker Wizard software
package (version 3.1, Bio-Rad Labs) was applied for peak
detection. Peaks were auto-detected when occurring in at
least 25% of spectra and when having a signal-to-noise
ratio of at least 5. Peak clusters were completed with peaks
with a signal-to-noise ratio of at least 2 in a cluster mass
window of 0.3%.
Biomarker characterisation
A 500 μl serum sample containing the biomarker of inter-
est marker (i.e. m/z 9198) was denatured in 9 M urea/2%
CHAPS/1% DTT in 50 mM Tris-HCl pH 9. The sample was
subsequently fractionated on Q Ceramic HyperD beads
with a strong anion exchange moiety (Biosepra Inc., Mal-
borough, MA, USA). After binding of denatured sample to
the beads, the flow through was collected and bound pro-
teins were subsequently eluted with buffers of pH 9 – 3.
The fraction containing the marker was further purified by
size fractionation, using Microcon 50 kDa MW spin con-
centrators (YM50, Millipore, Billerica, MA, USA) with
increasing concentrations of ACN/0.1% TFA. The filtrate
containing the m/z 9198 marker was subsequently de-
salted by application on reversed phase RP18 beads (Var-
ian Inc., Palo Alto, CA, USA), followed by elution with
increasing concentrations of ACN containing 0.1% TFA.
The purification process was monitored by profiling each
fraction on Q10 arrays and NP20 arrays (a non-selective,
silica chromatographic surface). Eluates containing the
m/z 9198 marker were dried and redissolved in loading
buffer for SDS-PAGE, which was performed on Novex
NuPage gels (18% Tris-Glycine gel; Invitrogen, San Diego,
CA, USA). Following Coomassie staining (Simply Blue;
Invitrogen), protein bands of interest were excised and
collected. The proteins within the excised bands were
eluted by washing twice with 30% ACN/100 mM ammo-
nium bicarbonate, followed by dehydration in 100%
ACN. Gel bands were subsequently heated at 50°C for 5
min and eluted with 45% formic acid/30% ACN/10% iso-
propanol under sonification for 30 min. After leaving the
eluates overnight at room temperature, they were profiled
on NP20 arrays. Eluates were subsequently dried, resus-
pended in 20 ng/μl trypsin (Promega, Madison, WI, USA)
in 10% ACN/25 mM ammonium bicarbonate, followed
by incubation at room temperature for 4 h for protein
digestion. For in-gel protein digestion, gel bands were first
washed with 40% methanol/10% acetic acid twice, fol-
lowed by a 30% ACN/100 mM ammonium bicarbonate
wash. Gel bands were dried by SpeedVac and digested for
12 h by trypsin (20 ng/μl 100 mM ammonium bicarbo-
nate). All tryptic digests were profiled on NP20 chips,
using 1 μl 20% alpha-cyano-4-hydroxy cinnaminic acid
solution in 50% ACN/0.5% TFA as matrix. Peptides in the
digests were investigated with the NCBI database using
the ProFound search engine at http://prowl.rockefel
ler.edu/prowl-cgi/profound.exe with the following search
parameters: standard cleavage rules for trypsin, 1 missed
cleavage allowed. Confirmation of protein identity was
provided by sequencing tryptic digest peptides by quadru-
pole-TOF (Q-TOF) MS (Applied Biosystems/MSD Sciex,
Foster City, CA, USA) fitted with a ProteinChip Interface.
Fragment ion spectra resulting from Q-TOF analyses were
taken to search the SwissProt 44.2 database (Homo Sapi-
ens: 11072 sequences) using the MASCOT search enginePage 3 of 15
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London, UK), with the following search parameters:
monoisotopic precursor mass tolerance: 40 ppm, frag-
ment mass tolerance: 0.2 Da, variable modifications:
methionine oxidation, and trypsin cleavage site. Through-
out the identification experiments, a serum sample lack-
ing the m/z 9198 marker was run concurrently as a
negative control.
Haptoglobin phenotyping assay
The haptoglobin (Hp) phenotype of all samples in set I
and II was assessed by native one-dimensional gel electro-
phoresis, followed by peroxidase staining. One μl of
serum or plasma sample was mixed with 19 μl of a 1:100
dilution of haemolysate in phosphate buffered saline. Fol-
lowing incubation for 5 min at room temperature, 10 μl
of 3× native sample buffer (30 ml glycerol/18.8 ml 1 M
Tris-HCl pH 6.8/1.5 ml 1% (w/v) bromophenol blue,
made to 100 ml with water) was added and mixed. Sam-
ples were then loaded onto a 3 – 8% gradient Tris-Acetate
NuPAGE precast gel (Invitrogen, Karlsruhe, Germany).
Samples were run at a constant 150 V, gradient 18 – 7 mA
for 3 h, using a running buffer of 25 mM Tris/250 mM gly-
cine, adjusted to pH 8.6. After staining with 1% (w/v)
rhodamine 1%, the gel was incubated for 10 min in a 1:1
water-diluted leucomalachite green peroxidase-develop-
ment buffer (0.2 g leucomalachite green/0.02 g EDTA in
25 ml 40% (v/v) acetic acid with 0.06% (v/v) H2O2). The
phenotype of each sample was subsequently determined
by its specific migration pattern, which appears as black
bands in the gel (Figure 1A) [12].
Statistical analysis
Survival curves were analysed according to the Kaplan-
Meier method from the date of randomisation to the time
of first recurrence or death, or the date of last follow-up.
The curves were compared by log-rank statistics. To inves-
tigate the relation of haptoglobin phenotype and other
variables with recurrence-free survival time, a Cox propor-
tional hazards model was used. Relations were expressed
in terms of hazard ratios with 95% confidence intervals.
Possible confounding clinical variables that either have
known prognostic or predictive value (i.e. treatment (high
dose vs. conventional dose chemotherapy), age (≥ 40 yrs
vs. < 40 yrs), number of positive lymph node (0 – 9 vs. ≥
10), tumour size (< 5 cm vs. ≥ 5 cm), Her2/Neu status
(negative vs. positive, of note, patients did not yet receive
adjuvant trastuzumab), receptor status (oestrogen and/or
progesterone receptor (ER/PR) positive vs. negative), and
Bloom-Richardson grade (grade I vs. grade II vs. grade
III)), or variables that were related to the exposure hap-
toglobin phenotype (i.e. surgery (breast conserving vs.
mastectomy)) were incorporated into the model.
The distribution of patient characteristics over the two
sample sets were compared using either the Chi-square
test or the Fisher's exact test for categorical variables and
the Mann-Whitney U test for continuous variables. All sta-
tistical analyses were performed using SPSS statistical soft-
ware, version 13.0 (SPSS Inc., Chicago, IL, USA) and SAS
statistical software, version 9.1.3 (SAS Institute Inc., Cary,
NC, USA). Statistical tests were two sided at the 5% level
of significance.
Results
Study population
At time of analysis, in sample set I (n = 63), 28 patients
had a recurrence or had died and 35 patients were cen-
sored at a median follow-up of 6.6 years. In sample set II
(n = 371), 149 patients had a recurrence or had died and
222 patients were censored at a median follow-up of 8.0
years. Characteristics of both sample sets are provided in
Table 1. All patient characteristics were similarly distrib-
uted between sample set I and sample set II, as deter-
mined by the Chi-square test or the Mann-Whitney U test.
Biomarker discovery
Following evaluation of several chromatographic array
surfaces with suitable binding conditions, the Q10 array
with 100 mM Tris-HCl pH 8/0.1% TritonX-100 as a bind-
ing buffer gave optimal results in our screening popula-
tion (n = 8). Using this SELDI-TOF MS assay, the spectra
of sera from patients experiencing no recurrence (n = 4)
could clearly be distinguished by the spectra of sera from
patients that recurred at a relatively short follow-up (n =
4) by overexpression of a peak at m/z 9198. The clear
dichotomous distribution in the relative m/z 9198 peak
intensity was subsequently confirmed in the acquired
mass spectra of all 63 sera in sample set I (peak intensity
> 20: n = 40, ≤ 20: n = 23). Representative SELDI-TOF MS
spectra are presented in Figure 2. The Kaplan-Meier curve
(Figure 3) shows a significant difference in the probability
of remaining recurrence free (Log-rank test, p = 0.0014)
between high-risk primary breast cancer patients exhibit-
ing a peak at m/z 9198 with a relative intensity > or ≤ than
20. The univariate hazard ratio was 3.22 (95% CI: 1.51 –
6.85, p = 0.0024).
Biomarker characterisation
Following anion exchange fractionation, the m/z 9198
marker was eluted in the pH 5 eluate. This fraction was
concentrated on YM50 spin concentrators, and the marker
was found in the water wash. De-salting of the water wash
on RP18 beads resulted in elution of the marker in the
60% ACN/0.1% TFA eluate, which was subsequently sub-
jected to SDS-PAGE analysis. After staining, a clear band
in the 9 kDa region was visible, which was excised and
subjected to passive elution followed by tryptic digestion
of the eluate. Profiling of the gel-eluate confirmed thePage 4 of 15
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digest identified the marker as haptoglobin alpha-1 chain
(estimated Z-score 1.49, 48% sequence coverage), which
is an 83 amino acid peptide with a theoretical mass of
9192.21 Da and a pI of 5.23. This identity [Swiss-
Prot:P00738] was confirmed by amino acid sequencing of
4 peptides in the tryptic digest by tandem MS on a Q-TOF
(76% coverage, Figure 4A).
Haptoglobin occurs in vivo as polymers of an alpha and
beta chain complex, interlinked via disulfide bridges.
There are two major alpha chains: alpha-1 (83 amino
acids, 9.2 kDa) and alpha-2 (142 amino acids, 16 kDa), of
which the alpha-2 chain is the product of unequal cross-
ing over between two alpha-1 alleles [13]. Due to this
genetic variation, haptoglobin occurs in three major
(pheno)types: Hp 1-1, Hp 2-1 and Hp 2-2, occurring in
16%, 48%, and 36%, respectively, of the northwestern
European population [14]. The Hp 1-1 phenotype con-
sists of an [alpha-1 – beta] dimer (86 kDa), whereas Hp 2-
1 consist of two [alpha-1 – beta] units flanking a variable
length [alpha-2 – beta] polymer (86 – 300 kDa). Hp 2-2,
Haptoglobin phenotype assessment using a native one-dimensional gel electrophoresis systemFigure 1
Haptoglobin phenotype assessment using a native one-dimensional gel electrophoresis system. A: Specific migra-
tion pattern of Hp 1-1, Hp 2-1, and Hp 2-2 in a 3 – 8% gradient Tris-Acetate gel. B: Composition of the three haptoglobin phe-
notypes Hp 1-1, Hp 2-1, and Hp 2-2 (adapted from [14]).
Hp α-1 chain Hp α-2 chain        Hp β chain
Hp 1-1     Hp 2-1     Hp 2-2 Hp 1-1               Hp 2-1                 Hp 2-2
A BPage 5 of 15
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Sample set I (n = 63) Sample set II (n = 371)
Patient characteristics N (%) N (%)
Age
Mean [range] 45.8 [33–55] 43.9 [26–55]
< 40 years 10 (16%) 94 (25%)
≥ 40 years 53 (84%) 277 (75%)
Menopausal status
Premenopausal 49 (78%) 317 (85%)
Postmenopausal 11 (17%) 40 (11%)
Unknown 3 (5%) 14 (4%)
Surgery
Mastectomy 56 (89%) 291 (78%)
Breast conserving 7 (11%) 80 (22%)
Treatment
Conventional dose 27 (43%) 158 (43%)
High dose 36 (57%) 213 (57%)
Tumour characteristics
Number of positive lymph nodes
4 – 9 40 (63%) 241 (65%)
≥ 10 23 (37%) 130 (35%)
Tumour size
T1 (< 2 cm) 9 (14%) 90 (24%)
T2 (2 – 5 cm) 41 (65%) 225 (61%)
T3 (= 5 cm) 13 (21%) 56 (15%)
Her2/Neu status
Negative 42 (67%) 274 (74%)
Positive 16 (25%) 81 (22%)
Unknown 5 (8%) 16 (4%)Page 6 of 15
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[alpha-2 – beta] unit (170 – 900 kDa) (Figure 1B) [15,16].
Expression of the Hp alpha-1 chain, as determined by
SELDI-TOF MS, will correspond to the actual haptoglobin
phenotype, since the haptoglobin alpha-1 chain is only
expressed by individuals with the Hp 1-1 or Hp 2-1 phe-
notype [12]. Indeed, following haptoglobin phenotype
assessment by native one-dimensional gel-electrophore-
sis, all patients with m/z 9198 = 20 carried the Hp 2-2
phenotype (n = 23), while patients with m/z 9198 > 20
were shown to have either the Hp 1-1 (n = 14) or Hp 2-1
(n = 26) phenotype (Figure 5).
Following Kaplan-Meier analysis by haptoglobin pheno-
type in sample set I (n = 63), the Hp 1-1, 2-1 and 2-2 phe-
notypes were shown to be associated with a good,
intermediate and poor prognosis, respectively (global
Log-rank test, p = 0.0029) (Figure 6). With Hp 1-1 pheno-
type as the reference category, the univariate hazard ratio
was 3.08 (95% CI: 0.67 – 14.10, p = 0.1464) for Hp 2-1,
and 7.37 (95% CI: 1.69 – 32.23, p = 0.0079) for Hp 2-2
phenotype. In the multivariate Cox regression analysis,
haptoglobin phenotype was independently associated
with recurrence free survival (Hp 2-2; p = 0.0098), while
for receptor status (ER/PR negative; p = 0.0962) and treat-
ment arm (conventional dose; p = 0.0509) a borderline
significant association was observed (Table 2).
Biomarker validation
The distribution of the haptoglobin phenotype of patients
in the validation sample set II (n = 371) was subsequently
assessed for validation purposes. As the haptoglobin phe-
notype (i.e. genotype) is not influenced by treatment,
samples in set II were collected at any time point in ther-
apy. All patient characteristics were similarly distributed
between sample set I and sample set II. The Hp 1-1, 2-1,
and 2-2 phenotype was determined in 70, 189, and 112
patients, respectively, yielding an allele frequency of 0.44,
which is in concordance with previously reported fre-
quencies. [14]
The Kaplan-Meier curve, however, did not show a signifi-
cant difference in the probability of recurrence free sur-
vival (global Log-rank test, p = 0.6158) between the high-
risk primary breast cancer patients in sample set II having
the Hp 1-1, 2-1 or 2-2 phenotype (Figure 7). With the Hp
1-1 phenotype as the reference category, the univariate
hazard ratio was 0.87 (95% CI: 0.56 – 1.34, p = 0.5221)
and 1.03 (95% CI: 0.65 – 1.64, p = 0.8966) for the Hp 2-
1 and Hp 2-2 phenotypes, respectively. This finding was
not affected by tumour size, which was found to be the
only independently associated variable for recurrence free
survival (p = 0.0374). Her2/Neu status (p = 0.0589) and
treatment arm (p = 0.0809) were only borderline signifi-
cantly associated with recurrence free survival in set II
(Table 2).
Discussion
The introduction of high-throughput analytical platforms,
such as the genomic/transcriptomic microarray technol-
ogy, or the proteomic SELDI-TOF MS technology, has ena-
bled the advent of discovery-based research. Large
quantities of data can now be analysed without underly-
ing hypotheses, to search for patterns that discriminate
between patients with different diagnosis, prognosis or
response to treatment. Assessment of validity, however, is
pivotal in this discovery-based '-omics' research, as the
meaning of such patterns from a biological perspective
often is unknown.
Our initial findings were, however, endorsed by the vari-
ous biological functions of haptoglobin and their pheno-
Oestrogen/Progesterone receptor status
ER and PR negative 10 (16%) 101 (27%)
ER and/or PR positive 50 (79%) 250 (68%)
Unknown 3 (5%) 20 (5%)
Bloom-Richardson grade
Grade I 13 (21%) 62 (17%)
Grade II 26 (41%) 112 (30%)
Grade III 20 (32%) 170 (46%)
Unknown 4 (6%) 27 (7%)
Table 1: Patient and tumour characteristics of sample set I and II (Continued)Page 7 of 15
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Representative example of serum protein profiles (sample set I) obtained with the optimized SELDI-TOF MS assay, showing the clear dichotomous expr ssion of the m/z 9198 peak (dot ed box)Figure 2
Representative example of serum protein profiles (sample set I) obtained with the optimized SELDI-TOF MS 
assay, showing the clear dichotomous expression of the m/z 9198 peak (dotted box).
8 0 0 0 9 0 0 0 1 0 0 0 0 1 1 0 0 0
8 0 0 0 9 0 0 0 1 0 0 0 0 1 1 0 0 0
Pt 1
Pt 2
Pt 3
Pt 4
Pt 5
Pt 6
Pt 7
Pt 8
0
25
50
75
0
25
50
75
0
25
50
75
0
25
50
75
0
25
50
75
0
25
50
75
0
25
50
75
0
25
50
75
R
e
la
ti
v
e
 i
n
te
n
si
ty
 →
Mass-to-charge ratio →
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haptoglobin is binding of free haemoglobin. The hap-
toglobin-haemoglobin complex is too large to be filtered
at the kidney glomerulus and is therefore retained. Both
iron loss and free-radical mediated damage, caused by the
haem-iron mediated generation of free hydroxyl radicals
(by means of the Fenton reaction: H2O2 + Fe2+ → Fe3+ +
OH- + ·OH) are thus prevented [14]. Haptoglobin has
also been identified as a strong angiogenic agent, activat-
ing endothelial cell growth and differentiation. This func-
tion was shown to be phenotype dependent, as the Hp 2-
2 phenotype has been found to be more angiogenic than
the other phenotypes [17]. The poor prognosis of our Hp
2-2 breast cancer patients in our discovery set (n = 63)
could be exerted via this haptoglobin function, since ang-
iogenesis is well known to be involved tumor growth, pro-
liferation, and metastasis [18].
Both haptoglobin and its phenotype have been described
previously in relation to various diseases (including can-
cer), a finding which is not surprising in view of its biol-
ogy. Both the intact protein and its subunits have been
found overexpressed in serum of patients with various
solid tumours, for example ovarian and small-cell lung
cancer [19-21]. The 9.2 kDa haptoglobin alpha-1 chain
has been specifically detected by Tolson et al. [12] in sera
of renal cell carcinoma patients and healthy controls. Fol-
lowing haptoglobin phenotyping, all patients having the
Hp 2-2 phenotype indeed proved to be missing the 9.2
kDa haptoglobin alpha-1 peak in their serum protein pro-
file. Due to its phenotypic distribution, this protein could,
however, not be considered as a diagnostic marker. The
influence of haptoglobin phenotype on recurrence free
survival has not been investigated. [12] Using the SELDI-
TOF MS platform, the 9.2 kDa alpha-1 chain was also
Recurrence free survival in sample set I (n = 63) according the m/z 9198 peak intensity > 20 or ≤ 20, as determined by SELDI-TOF MSFig e 3
Recurrence free survival in sample set I (n = 63) according the m/z 9198 peak intensity > 20 or ≤ 20, as deter-
mined by SELDI-TOF MS.
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Structural identification of the m/z 9198 peak clusterFigure 4
Structural identification of the m/z 9198 peak cluster. A. Peptide mapping of the m/z 9198 marker. MS spectrum of the 
m/z 9198 tryptic digest in the gel eluate. All peptides were sequenced with tandem MS using Q-TOF for confirmation. Results 
from the MASCOT search for protein identification include start and end positions of the peptide sequence starting from the 
amino acid terminal of the whole protein, the observed m/z, transformed to its experimental mass (Mr(expt)), the calculated 
mass (Mr(calc)) from the matched peptide sequence, as well as their mass difference (Delta), the number of missed cleavage 
sites for trypsin (Miss), the estimate Z-score and its significance, and the peptide sequence. B. Matched amino acid sequence of 
the m/z 9198 marker (in grey: amino acid sequence sequenced by Q-TOF MS), haptoglobin alpha-1 chain and the correspond-
ing N-terminus of haptoglobin-related-protein (in grey: amino acid substitutions between haptoglobin and haptoglobin-related-
protein) [24].
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Start -End Mr (obs)  Mr (expt )  Mr (calc)  Delt a Miss Score Expect  Sequence 
35 – 49 1590.70 1589.69 1589.79 -0.10 0 69 0.0014 K.PPEIAHGYVEHSVR.Y 
58 – 72 1708.80 1708.79 1707.84 -0.05 1 42 0.0041 K.LRTEGDGVYTLNNEK.Q 
78 – 94 1743.75 1742.74 1742.87 -0.13 0 60 0.0110 K.AVGDKLPECEAVCGKPK.N 
19 – 49 3292.61 3291.60 3291.51 0.09 0 98 2.3·10-8 A.VDSGNDVTDIADDGCPKPPEIAHGYVEHSVR.Y 
Amino acid sequence of m/z 9198 haptoglobin alpha-1 chain (start: 18 – end: 101, 76% sequence coverage): 
VDSGNDVTDI ADDGCPKPPE IAHGYVEHSV RYQCKNYYKL RTEGDGVYTL NNEKQWINKA VGDKLPECEA VCGKPKNPAN PVQ 
 
B: Comparison of  amino acid sequences 
m/ z 9198 marker 
VDSGNDVTDI ADDGCPKPPE IAHGYVEHSV RYQCKNYYKL RTEGDGVYTL NNEKQWINKA VGDKLPECEA VCGKPKNPAN PVQ 
Haptoglobin alpha-1 chain (Mw 9192.21, pI  5.23) 
VDSGNDVTDI ADDGCPKPPE IAHGYVEHSV RYQCKNYYKL RTEGDGVYTL NNEKQWINKA VGDKLPECEA VCGKPKNPAN PVQ 
Haptoglobin-relat ed-prot ein (Mw 9492.64, pI  6.76) 
LYSGNDVTDI SDDRFPKPPE IANGYVEHLF RYQCKNYYRL RTEGDGVYTL NDKKQWINKA VGDKLPECEA VCGKPKNPAN PVQ 
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BMC Cancer 2008, 8:389 http://www.biomedcentral.com/1471-2407/8/389detected by Goncalves et al. [9]. Unlike our own observa-
tions, they found the 9.2 kDa peak to be overexpressed in
sera of high-risk primary breast cancer patients (n = 81)
experiencing a relapse versus long-term disease free survi-
vors [9]. The absolute intensities of the m/z 9192 peak in
SELDI-TOF MS spectra of Goncalves et al. [9] ranged
between 0 and 2, and a clear dichotomous peak intensity
distribution was not observed. These discrepancies from
our initial findings most likely originate in the serum pre-
fractionation that was performed in this study. During
protein purification, we repeatedly found the 9.2 kDa
peak to be predominantly present in the pH 5 fraction.
Goncalves et al. [9] however, subjected only the pH 9/
flow through, pH 4, and organic solvent fractions to
SELDI-TOF MS analysis, resulting in a suboptimal assay
for haptoglobin alpha-1 detection.
Another association between protein expression and
recurrence free survival in breast cancer has previously
been reported by Kuhajda et al. [22,23]. They described a
decreased tumour tissue expression of haptoglobin-
related-protein, quantitated immunohistochemically, to
be associated with a prolonged recurrence free survival in
70 breast cancer patients [22]. Their findings differ from
our observations by the biological matrix analysed
(tumour tissue vs. serum), by the exposure used for pre-
diction of recurrence free survival (protein expression vs.
phenotype), and by the identity of the protein used for
prognostication (haptoglobin-related-protein vs. hap-
toglobin). Although coded for by two different genes,
both proteins have more than 90% amino acid sequence
homology. There are, however, distinct differences
between the alpha-1 chain of haptoglobin and hap-
toglobin-related-protein, due to 8 amino acid substitu-
tions [24]. Amino acid sequencing of the m/z 9198
marker, taking 7 out of 8 amino acid substitutions into
account, enabled us to unequivocally identify our candi-
date biomarker as haptoglobin alpha-1 chain (Figure 4B).
The haptoglobin phenotype has not been identified as a
predictor of recurrence free survival in breast cancer thus
far. The phenotype has nevertheless been associated with
clinical outcome of other pathologies, a.o. mortality [25],
nephropathy [26], and cardiovascular disease outcome in
diabetic patients [27], mortality in HIV infection [28] and
mortality in tuberculosis [29]. In these studies, the Hp 2-
2 phenotype was invariably associated with worse clinical
outcome, in contrast though to the study of Depypere et
al. [30], who found the Hp 1-1 phenotype associated with
more severe hypertension and proteinuria in patients with
preeclampsia.
Despite the potential biological justifications, our promis-
ing initial result of the haptoglobin phenotype being a
predictor of recurrence free survival in a limited number
(n = 63) of high-risk primary breast cancer patients was
not confirmed following validation by analysis of a six-
fold larger sample set (n = 371). It is unlikely that our
findings result from differences in patient characteristics
between our discovery and validation sample set, since all
(known) characteristics were similarly distributed
between both sample sets.
The two major threats to validity of discovery-based pro-
teomics research come from chance and bias [31]. Sources
of bias include differences in sample collection and stor-
age, or in analysis [32]. The haptoglobin phenotype how-
ever, is not influenced by specimen collection and storage.
Besides, the native 1D-gelelectrophoresis method for
Peak intensity of the m/z 9198 marker (as determined by SELDI-TOF MS) vs. haptoglobin phenotype (as assessed by 1D gel-electrophor sis) f samples i  set IFigure 5
Peak intensity of the m/z 9198 marker (as deter-
mined by SELDI-TOF MS) vs. haptoglobin phenotype 
(as assessed by 1D gel-electrophoresis) of samples in 
set I.
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BMC Cancer 2008, 8:389 http://www.biomedcentral.com/1471-2407/8/389Table 2: Multivariable proportional-hazards analyses for the risk of recurrence for patients in sample set I and II
Variable Sample set I (n = 63) Sample set II (n = 371)
HRa (95% CIb) p-value HRa (95% CIb) p-value
Haptoglobin phenotype
Hp 1-1 1 - - 1 - -
Hp 2-1 4.21 (0.44 – 39.83) 0.2105 0.94 (0.58 – 1.52) 0.8059
Hp 2-2 17.76 (2.00 – 157.44) 0.0098 1.26 (0.76 – 2.08) 0.3653
Surgery
Breast conserving 1 - - 1 - -
Mastectomy 1.26 (0.24 – 6.67) 0.7843 0.91 (0.59 – 1.39) 0.6514
Treatment arm
High dose 1 - - 1 - -
Conventional dose 0.33 (0.11 – 1.00) 0.0509 1.36 (0.96 – 1.92) 0.0809
Age
≥ 40 yrs 1 - - 1 - -
< 40 yrs 1.26 (0.32 – 4.93) 0.7413 0.97 (0.65 – 1.46) 0.8890
No. of positive lymph nodes
4 – 9 1 - - 1 - -
≥ 10 0.72 (0.23 – 2.29) 0.5785 1.00 (0.69 – 1.45) 0.9964
Tumour size
< 5 cm 1 - - 1 - -
≥ 5 cm 1.35 (0.50 – 3.65) 0.5497 1.63 (1.03 – 2.60) 0.0374
Her2/Neu status
Negative 1 - - 1 - -
Positive 1.47 (0.53 – 4.08) 0.4641 1.47 (0.99 – 2.20) 0.0589
Receptor status
ER/PR positive 1 - - 1 - -
ER/PR negative 3.39 (0.80 – 14.27) 0.0962 1.11 (0.73 – 1.70) 0.6138
Bloom-Richardson grade
Grade I 1 - - 1 - -Page 12 of 15
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BMC Cancer 2008, 8:389 http://www.biomedcentral.com/1471-2407/8/389assessment of haptoglobin phenotype is robust and repro-
ducible [33]. Study results are therefore unlikely to have
been influenced by bias, but rather result from chance.
Due to small sample sizes and the artifice of discovery
strategies, many biomarker candidates are prone to be
false positive, i.e. be a type I error (erroneous rejection of
the null hypothesis). The chance of candidate biomarkers
being type I errors is inferred by the fact that most pro-
teomic datasets are subject to both the 'curse of dimen-
sionality' (large number of features) and the 'curse of
dataset sparsity' (limited number of samples) [34]. As
such, datasets are frequently subjected to multiple testing
in search for candidate biomarkers. Yet, even a level of sig-
nificance for type I errors of 0.01 is no guarantee that false
positive findings are debarred, even following correction
for multiple testing. Problems caused by chance are best
avoided by analysis of an independent validation dataset,
in which false positive markers will be ruled out, as they
are unique to the discovery sample set [32,35].
Grade II 0.92 (0.26 – 3.23) 0.9016 0.87 (0.50 – 1.50) 0.6187
Grade III 1.28 (0.37 – 4.46) 0.6946 1.34 (0.79 – 2.26) 0.2796
aHR: Hazard Ratio, bCI: Confidence Interval
Table 2: Multivariable proportional-hazards analyses for the risk of recurrence for patients in sample set I and II (Continued)
Recurrence free survival in sample set I (n = 63) by haptoglobin phenotypeFig e 6
Recurrence free survival in sample set I (n = 63) by haptoglobin phenotype.
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BMC Cancer 2008, 8:389 http://www.biomedcentral.com/1471-2407/8/389The above-mentioned hurdles in proteomics research
apply equally to all other '-omics' research (e.g. genomics
and metabolomics), as in general, these research
approaches suffer from a limited number of samples in
comparison with the large number of generated features.
Conclusion
In conclusion, although we initially found the hap-
toglobin phenotype to be a predictor of recurrence free
survival in a limited number of high-risk primary breast
cancer patients, this was not confirmed following valida-
tion by analysis of a similar, but six-fold larger sample set.
Clearly, validation of initial results is of pivotal impor-
tance in determining the clinical significance of a candi-
date biomarker. In spite of this, few, if any, related clinical
diagnostic tests have yet been validated for clinical use,
although the number of papers reporting on candidate
protein biomarkers is large and still expanding. This lack
of validation can result in chance results and erroneous
conclusions, leading to disappointment when results can-
not be reproduced [36]. Distillation of true positives from
the total pool of candidate biomarkers is the single great-
est challenge in biomarker development, and should
therefore be the emphasis in data-driven proteomics
research.
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